Biperiden Hydrochloride

CHEMBL1201035 Phase 4 승인됨 Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
347.9 g/mol
LogP
Phase
4

The hydrochloride salt of biperiden, used to manage Parkinson's disease symptoms and medication-induced movement side effects. It works by blocking acetylcholine's action in brain regions controlling movement. It may impair cognition, particularly in elderly patients.

분자량

347.9000 g/mol

TPSA

23.50 Ų

치료 영역

작용 기전

Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

기전

Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

2D 구조

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

Cl.OC(CCN1CCCCC1)(c1ccccc1)C1CC2C=CC1C2

InChI

InChI=1S/C21H29NO.ClH/c23-21(19-7-3-1-4-8-19,11-14-22-12-5-2-6-13-22)20-16-17-9-10-18(20)15-17;/h1,3-4,7-10,17-18,20,23H,2,5-6,11-16H2;1H

Molecular Formula

C21H30ClNO

HBD / HBA

2 / 2

회전 가능 결합

5

무거운 원자

24

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

자주 묻는 질문

The hydrochloride salt of biperiden, used to manage Parkinson's disease symptoms and medication-induced movement side effects. It works by blocking acetylcholine's action in brain regions controlling movement. It may impair cognition, particularly in elderly patients.

Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

Yes, Biperiden Hydrochloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201035. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 92151. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

의학적 면책조항

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.